Hematologic Oncology

At more than 40 months’ follow-up, combining obinutuzumab with chemotherapy in the first-line setting reduced the risk of disease progression or death by 32% versus rituximab plus chemotherapy in patients with follicular lymphoma.

Combining the novel BTK inhibitor BGB-3111 with the CD-20 antibody obinutuzumab demonstrated clinical activity and was well tolerated in patients with chronic lymphocytic leukemia/small lymphocytic leukemia or follicular lymphoma.

Avelumab (Bavencio) demonstrated clinical activity and an acceptable safety and tolerability profile in heavily pretreated patients with classical Hodgkin lymphoma.

Clemens A. Schmitt, MD, director and professor at Berlin School of Integrative Oncology, discusses a conceptually novel treatment approach to classical Hodgkin lymphoma.

Copanlisib (BAY 80-6946), a novel PI3K inhibitor, is being combined with standard rituximab-based regimens in patients with relapsed, indolent non-Hodgkin lymphoma.

High levels of response were observed with nivolumab (Opdivo), regardless of previous treatment with brentuximab vedotin (Adcetris), in patients with relapsed/refractory Hodgkin lymphoma after autologous stem-cell transplant.

Pembrolizumab (Keytruda) demonstrated antitumor activity in the majority of patients with recurrent/refractory primary mediastinal large B-cell lymphoma.

Although FLT3 mutations are well established as a prognostic marker in patients with AML, efforts to target the aberration therapeutically were underway for more than 15 years before yielding success.

Sarah Rutherford, MD, discusses rare DLBCL subtypes, ongoing research to improve outcomes for these patient populations, and the potential role of CAR T-cell therapy.

Constantine S. Tam, MD, discusses phase III PCYC-1143 trial is investigating the combination of ibrutinib and venetoclax as well as the next steps with venetoclax /ibrutinib and other rational combinations in MCL.

Tisagenlecleucel-T (CTL019) met its primary endpoint for best objective response rate in patients with relapsed or refractory diffuse large B-cell lymphoma.

Connie Batlevi, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses safety results of a phase I study evaluating the combination of ibrutinib (Imbruvica) and buparlisib in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

Brad S. Kahl, MD, professor, Department of Medicine, Oncology Division, Washington University School of Medicine, discusses ADCT-402 for patients with relapsed/refractory B-cell lineage non-Hodgkin lymphoma.

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the phase II and phase III studies investigating the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

Results from a phase I/II study demonstrated that enasidenib (AG-221) is well-tolerated and associated with a median overall survival of more than 9 months in patients with IDH2-mutated relapsed/refractory acute myeloid leukemia.

John C. Byrd, MD, sheds light on the game-changing efficacy of ibrutinib in chronic lymphocytic leukemia.

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.

The FDA’s Oncologic Drugs Advisory Committee has scheduled a public hearing to discuss a biologics license application for tisagenlecleucel-T for patients aged 3 to 25 years with relapsed/refractory B-cell acute lymphoblastic leukemia.

This is the first case report of hemophagocytic lymphohistiocytosis complicating a nodular lymphocyte–predominant Hodgkin lymphoma in an adult treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.

The FDA has accepted a new drug application from Jazz Pharmaceuticals, granting priority review to the company’s novel CPX-351 injection (Vyxeos) for acute myeloid leukemia.